Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 12, 2015, Pages 1237-1245

  Szajewska, H ^a   Horvath, A ^a   Kolodziej M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

APHTHOUS STOMATITIS; ARTICLE; BLOATING; BLURRED VISION; CONSTIPATION; DIARRHEA; DRUG EFFICACY; EPIGASTRIC PAIN; ERADICATION THERAPY; ERUCTATION; HEART PALPITATION; HELICOBACTER INFECTION; HUMAN; LOSS OF APPETITE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SACCHAROMYCES BOULARDII; SUPPLEMENTATION; SYSTEMATIC REVIEW; TASTE DISORDER; URTICARIA; VOMITING; XEROSTOMIA; CHILD; DRUG COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; SACCHAROMYCES;

ANTI-BACTERIAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SACCHAROMYCES;

EID: 84929296351     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13214     Document Type: Article

References (33)

1. Graham DY, Lee YC, Wu MS,. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86.e3; discussion e12-3.
2. Malfertheiner P, Megraud F, O'Morain CA, et al,. European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
3. Zhu R, Chen K, Zheng YY, et al,. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014; 20: 18013-21.
4. Dang Y, Reinhardt JD, Zhou X, Zhang G,. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS ONE 2014; 9: e111030.
5. Li S, Huang XL, Sui JZ, et al,. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr 2014; 173: 153-61.
6. Szajewska H, Horvath A, Piwowarczyk A,. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-79.
7. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
8. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org (accessed 1 February 2015).
9. Schünemann H, Brozek J, Guyatt G, Oxman A, eds. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available at: www.guidelinedevelopment.org/handbook. (accessed March 2015).
10. Egger M, Smith GD, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
11. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S,. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309-16.
12. Cremonini F, di Caro S, Covino M, et al,. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744-9.
13. Duman DG, Bor S, Ozütemiz O, et al,. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17: 1357-61.
14. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y,. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr 2009; 98: 127-31.
15. Song MJ, Park DI, Park JH, et al,. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15: 206-13.
16. Zhao HM, Ou-Yang HJ, Duan BP, et al,. Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children. Zhongguo Dang Dai Er Ke Za Zhi 2014; 16: 230-3.
17. Zojaji H, Ghobakhlou M, Rajabalinia H, et al,.: The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H. pylori: a randomized controlled trial. Gastroenterol Hepatol Bed Bench 2013; 6 (Suppl. 1): S99-104.
18. Kyriakos N, Papamichael K, Roussos A, et al,. A lyophilized form of Saccharomyces boulardii enhances the Helicobacter pylori eradication rates of omeprazole-triple therapy in patients with peptic ulcer disease or functional dyspepsia. Hospital Chronicles 2013; 8: 1-7.
19. Chu Y, Zhu H, Zhou Y, Lv L, Hu J,. Intervention study on Saccharomyces boulardii with proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori related peptic ucer. African J Pharm Pharmacol 2012; 6: 2900-4.
20. Gao C, Xie R, Ma T, Wu S,. Therapeutic effect of Saccharomyces boulardii combined with standard triple therapy for Helicobacter pylori eradication. Chin J Gastroenterol 2012; 17: 555-7.
21. Lee JY, Choi SP, Park JH, Shin JW, Joo YH,. The effect of Saccharomyces boulardii as an adjuvant to the 14-day triple therapy for eradication of Helicobacter pylori. J Gastroenterol Hepatol 2011; 26 (Suppl. 5): 257.
22. Whelan K, Myers CE,. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 2010; 91: 687-703.
23. Zheng X, Lyu L, Mei Z,. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013; 105: 445-53.
24. Szajewska H, Mrukowicz J,. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005; 22: 365-72.
25. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH,. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011. doi: 10.1002/14651858.CD004827.pub3
26. McFarland LV,. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16: 2202-22.
27. Wu JY, Liou JM, Graham DY,. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014; 8: 21-8.
28. Graham DY, Lu H, Yamaoka Y,. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
29. Graham DY, Fischbach LA,. Letter: the ethics of using inferior regimens in H. pylori randomised trials. Aliment Pharmacol Ther 2012; 35: 852-4.
30. O'Connor JP, O'Morain CA,. Letter: the ethics of using inferior regimens in H. pylori randomised trials-invited comment. Aliment Pharmacol Ther 2012; 35: 858.
31. Pounder RE, Talley NJ,. Letter: the ethics of using inferior regimens in H. pylori randomised trials-editor's reply. Aliment Pharmacol Ther 2012; 35: 854-6.
32. Graham DY, Dore MP,. Helicobacter pylori therapy demystified. Helicobacter 2011; 16: 343-5.
33. Molina-Infante J, Lucendo AJ, Angueira T, et al,. European Registry on H. pylori management (Hp-EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41: 581-9.